The interleukin‐1 receptor antagonist anakinra improves first‐phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Inflammation at the level of the β cell appears to be involved in progressive β‐cell dysfunction in type 2 diabetes. We assessed the effect of blocking interleukin‐1 ( IL ‐1) by anakinra [recombinant human interleukin‐1 receptor antagonist (IL‐1Ra)] on β‐cell function. Sixteen participants with impaired glucose tolerance were treated with 150 mg anakinra daily for 4 weeks in a double blind, randomized, placebo‐controlled cross‐over study with a wash‐out period of 4 weeks. At the end of each treatment period, oral glucose tolerance tests ( OGTTs ) and hyperglycaemic clamps were performed. First‐phase insulin secretion improved after anakinra treatment compared with placebo, 148 ± 20 versus 123 ± 14 mU/l, respectively (p = 0.03), and the insulinogenic index was higher after anakinra treatment. These results support the concept of involvement of IL ‐1β in the (progressive) decrease of insulin secretion capacity associated with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s062 · Cited by 5,491
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798 · cited 2×
“Blocking the effects of IL-1 in patients with type 2 diabetes mellitus by anakinra, a recombinant human IL-1Ra, has been shown to improve glycaemic control through enhanced β cell function [6].”
BackgroundResultGerich, J. E. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.4.447 · Cited by 222 · cited 1×
“Type 2 diabetes mellitus occurs when β cells fail to appropriately increase insulin secretion in response to insulin resistance [1].”
BackgroundCnop, M., Vidal, J., Hull, R. L., Utzschneider, K. M., Carr, D. B., Schraw, T., Scherer, P. E., Boyko, E. J., Fujimoto, W. Y., & Kahn, S. E. (2007) · Diabetes Care · doi:10.2337/dc06-1834 · Cited by 174
Cited by
Inflammation in obesity, diabetes, and related disorders
Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.013 · Cited by 2,066
The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives
Tsalamandris, S., Antonopoulos, A. S., Oikonomou, E., Papamikroulis, G.-A., Vogiatzi, G., Papaioannou, S., Deftereos, S., & Tousoulis, D. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.33.1 · Cited by 1,381
Antar, S. A., Ashour, N. A., Sharaky, M., Khattab, M., Ashour, N. A., Zaid, R. T., Roh, E. J., Elkamhawy, A., & Al-Karmalawy, A. A. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115734 · Cited by 622
Targeting innate immune mediators in type 1 and type 2 diabetes
Donath, M. Y., Dinarello, C. A., & Mandrup-Poulsen, T. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0213-9 · Cited by 416
Frankowski, R., Kobierecki, M., Wittczak, A., Różycka-Kosmalska, M., Pietras, T., Sipowicz, K., & Kosmalski, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119677 · Cited by 58
Metadata
- Authors
- van Poppel, P. C. M., van Asseldonk, E. J. P., Holst, J. J., Vilsbøll, T., Netea, M. G., & Tack, C. J.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2014-08-13
- Volume
- 16
- Issue
- 12
- Pages
- 1269-1273
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1997970555
- Cited by
- 58
- References
- 5
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The interleukin‐1 receptor antagonist anakinra improves first‐phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance. https://app.cochat.ai/papers/10.1111/dom.12357
- The paper
- van Poppel, P. C. M., van Asseldonk, E. J. P., Holst, J. J., Vilsbøll, T., Netea, M. G., & Tack, C. J. (2014). The interleukin‐1 receptor antagonist anakinra improves first‐phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12357
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.